Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti‐β7 integrin therapy for inflammatory bowel disease
Open Access
- 30 March 2018
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 47 (11) , 1440-1452
Abstract
Summary: Background: Novel treatments with superior benefit‐risk profiles are needed to improve the long‐term prognosis of patients with inflammatory bowel disease (IBD). Etrolizumab—a monoclonal antibody that specifically targets β7 integrins—is currently under phaseIIIclinical evaluation inIBD.Aim: This review summarises the available pharmacological and pharmacokinetic/pharmacodynamic data for etrolizumab to provide a comprehensive understanding of its mechanism of action (MOA) and pharmacological effects.Methods: Published and internal unpublished data from nonclinical and clinical studies with etrolizumab are reviewed.Results: Etrolizumab exerts its effect via a unique dualMOAthat inhibits both leucocyte trafficking to the intestinal mucosa and retention within the intestinal epithelial layer. The gut‐selectivity of etrolizumab results from its specific targeting of the β7 subunit of α4β7 and αEβ7 integrins. Etrolizumab does not bind to α4β1 integrin, which mediates lymphocyte trafficking to tissues including the central nervous system, a characteristic underlying its favourable safety with regard to progressive multifocal leucoencephalopathy. Phase I/IIstudies in patients with ulcerative colitis (UC) showed linear pharmacokinetics when etrolizumab was administered subcutaneously at 100 mg or higher once every 4 weeks. This dose was sufficient to enable full β7 receptor occupancy in both blood and intestinal tissues of patients with moderate to severe UC. The phaseIIstudy results also suggested that patients with elevated intestinal expression of αE integrin may have an increased likelihood of clinical remission in response to etrolizumab treatment.Conclusion: Etrolizumab is a gut‐selective, anti‐β7 integrin monoclonal antibody that may have therapeutic potential for the treatment ofIBD.Keywords
Funding Information
- Genentech,Inc.
This publication has 78 references indexed in Scilit:
- Dietary gluten triggers concomitant activation of CD4 + and CD8 + αβ T cells and γδ T cells in celiac diseaseProceedings of the National Academy of Sciences, 2013
- A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitisGut, 2012
- A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytesBritish Journal of Pharmacology, 2011
- Progressive Multifocal Leukoencephalopathy and Newer Biological AgentsDrug Safety, 2010
- CNS Elevation of Vascular and Not Mucosal Addressin Cell Adhesion Molecules in Patients with Multiple SclerosisThe American Journal of Pathology, 2010
- Anti-integrin monoclonal antibodiesJournal of Cell Science, 2009
- α4 Integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditionsJournal of Neuroimmunology, 2009
- Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and PharmacokineticsClinical Pharmacology & Therapeutics, 2009
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- IntegrinsCell, 2002